Koyfin Home > Directory > Health Care > Aerie Pharmaceuticals > EBITDA / Interest Expenses

Aerie Pharmaceuticals EBITDA / Interest Expenses Chart (AERI)

Aerie Pharmaceuticals annual/quarterly EBITDA / Interest Expenses from 2012 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Aerie Pharmaceuticals EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-5m a -17.33% increase of 1m year over year
  • Aerie Pharmaceuticals EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-6m a -213.84% increase of 12m year over year
  • Aerie Pharmaceuticals Annual EBITDA / Interest Expenses for 2019 was $-11m a -655.45% increase of 70m from 2018
  • Aerie Pharmaceuticals Annual EBITDA / Interest Expenses for 2018 was $-81m a 53.48% decrease of -43m from 2017
  • Aerie Pharmaceuticals Annual EBITDA / Interest Expenses for 2016 was $-38m a 20.59% decrease of -8m from 2015
Other Ratios Metrics:
  • Aerie Pharmaceuticals Total Debt / Capital for the quarter ending June 06, 2018 was $39m a -12.45% decrease of -5m year over year
  • Aerie Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $6m a 11.47% increase of 1m year over year
  • Aerie Pharmaceuticals Total Debt / Equity for the quarter ending June 06, 2018 was $64m a -22.13% decrease of -14m year over year
View Chart On Koyfin

Quarterly AERI EBITDA / Interest Expenses Data

06/2020$-5m
03/2020$-5m
12/2019$-6m
09/2019$-6m
06/2019$-26m
03/2019$-55m
12/2018$-63m
09/2018$-79m
06/2018$-119m
03/2018$-80m

Annual AERI EBITDA / Interest Expenses Data

2019$-11m
2018$-81m
2016$-38m
2015$-30m
2014$-79m
2013$-6m
2012$-189m
2011$-129m